Planned Androgen-Deprivation Therapy Duration and Calculated 3-Year Major Osteoporotic Fracture Risk After Fracture Risk Assessment Tool Evaluation in Nonmetastatic Prostate Cancer: A Model-Based Analysis
Cancer Treatment and Research Communications · 2026-11 · 101546
DOI: 10.1016/j.ctarc.2026.101546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Motohiro Fujiwara und 10 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Fujiwara, M., Yoshida, S., Yajima, S., Chen, W., Sato, H., Hirakawa, A., Fukushima, H., Arita, Y., Yasuda, Y., Yokoyama, M., & Fujii, Y. (2026). Planned Androgen-Deprivation Therapy Duration and Calculated 3-Year Major Osteoporotic Fracture Risk After Fracture Risk Assessment Tool Evaluation in Nonmetastatic Prostate Cancer: A Model-Based Analysis. Cancer Treatment and Research Communications, 101546. https://doi.org/10.1016/j.ctarc.2026.101546
Vancouver
Fujiwara M, Yoshida S, Yajima S, Chen W, Sato H, Hirakawa A, et al. Planned Androgen-Deprivation Therapy Duration and Calculated 3-Year Major Osteoporotic Fracture Risk After Fracture Risk Assessment Tool Evaluation in Nonmetastatic Prostate Cancer: A Model-Based Analysis. Cancer Treatment and Research Communications. 2026:101546. doi:10.1016/j.ctarc.2026.101546
BibTeX
@article{Fujiwara2026,
author = {Fujiwara, Motohiro and Yoshida, Soichiro and Yajima, Shugo and Chen, Wei and Sato, Hiroyuki and Hirakawa, Akihiro and Fukushima, Hiroshi and Arita, Yuki and Yasuda, Yosuke and Yokoyama, Minato and Fujii, Yasuhisa},
title = {Planned Androgen-Deprivation Therapy Duration and Calculated 3-Year Major Osteoporotic Fracture Risk After Fracture Risk Assessment Tool Evaluation in Nonmetastatic Prostate Cancer: A Model-Based Analysis},
journal = {Cancer Treatment and Research Communications},
year = {2026},
pages = {101546},
doi = {10.1016/j.ctarc.2026.101546}
}
EUVIMED